Introduction
Dimethyl fumarate (DMF) and fingolimod (FTY) are two commonly prescribed oral disease modifying therapies (DMTs) approved for the treatment of relapsing multiple sclerosis (MS). Separate phase 3 randomized clinical trials (RCTs) for DMF and FTY showed similar efficacy when compared to placebo, including reductions in annualized relapse rate (ARR) of 44%-53% for DMF and 48%-54% for FTY. [1] [2] [3] [4] Furthermore, DMF and FTY both demonstrated superior efficacy when compared to injectable therapies. A post-hoc comparison of DMF versus glatiramer acetate showed significant reductions in ARR and number of new/enlarging T2-hyperintense lesions over 24 months. 2 Additionally, in two 12month head-to-head RCTs, FTY showed improved efficacy with respect to ARR compared to interferon beta-1a and glatiramer acetate. 3, 5 However, there are notable differences in adverse events (AEs) and tolerability profiles between DMF and FTY that lead to variable prescribing patterns in real world practice. DMF is commonly associated with flushing and gastrointestinal (GI) side effects that are most prominent within the first 1-2 months of treatment. 1, 2 Typical FTY AEs include mild to moderate upper respiratory tract infections, headaches, and back pain. 3, 4 Additionally, rare serious AEs related to FTY include second degree heart block, cryptococcal meningitis, fatal herpesvirus infections, and macular edema. 4 Both DMTs are associated with a rare risk of progressive multifocal leukoencephalopathy (PML). 6, 7 Currently, there is no consensus on the sequencing of MS therapies, resulting in variable use of DMTs in routine practice. The comparative effectiveness of certain MS DMTs is currently unknown, and indirect comparisons of oral DMTs showed conflicting results. [8] [9] [10] Observational studies harnessed from real-world data from clinical practice have valuable implications in decision-making and can answer clinically relevant questions with broad applicability.
Previous real-world studies directly comparing DMF and FTY largely demonstrated similar effectiveness between these DMTs [11] [12] [13] [14] [15] [16] [17] and an increased likelihood of DMF discontinuation up to 30 months. [11] [12] [13] [14] [15] [16] [17] [18] However, to date, there are no published comparative effectiveness studies investigating J o u r n a l P r e -p r o o f adjusted analyses to reduce the impact of confounding and certain biases prior to reporting treatment effect differences. 19 
Methods

Patient Population
This retrospective observational study followed MS patients treated with either DMF or FTY at the Cleveland Clinic Mellen Center or the Rocky Mountain MS Center at the University of Colorado (RMMSC at CU). Patients treated at Cleveland Clinic were selected from those starting DMF or FTY within one year of their respective FDA approval. Patients treated at RMMSC at CU were selected from those starting DMF or FTY prior to October 2013. Patients starting DMF and FTY received counseling per standard of care on possible side effects and mitigation strategies. Occasionally, slower DMF titration schedules were implemented at our sites to alleviate AEs, though these data were not consistently captured in this study population. Patients with progressive MS were included in this study to reflect the real-world experience of patients treated in clinical practice. A subgroup analysis was conducted on relapsing-remitting MS (RRMS) patients to better comment on comparative outcomes in a more inflammatory population. An additional analysis was conducted on patients who discontinued DMF and FTY within 36 months of follow-up to comment on sequencing practices and comparative effectiveness in patients switching to injectable/oral therapies versus escalating treatment to highly effective agents.
Data Collection
Following institutional review board approval at each site, the electronic medical records (EMR) of patients who met the inclusion criteria were retrospectively reviewed. Baseline data within 12 months of DMF/FTY initiation and outcomes data up to 36 months after DMT initiation were collected. Patients who discontinued DMF or FTY by ≤ 36 months with available data were retrospectively followed for an additional 12 months from DMT discontinuation.
Post-baseline follow-up (e.g. MRI frequency/protocols and visits) was similar between groups.
For the purpose of this study, clinical relapses were defined as new or worsening neurological symptoms lasting greater than 24 hours, without a coexistent illness or fever. Relapses were determined via clinician report in the available patient charts. The number of new T2-hyperintense brain lesions and J o u r n a l P r e -p r o o f semi-quantitative assessment of overall lesion burden were determined manually by C.M.H. at Cleveland Clinic, B.V. at RMMSC at CU, and neuroradiologists at each institution.
Cleveland Clinic data were stored on a secure server using Redcap Software. RMMSC at CU data were encrypted and stored on a secure server using Excel. Data were de-identified by each center prior to being merged into a single Excel database for analysis.
Outcome Measures
The primary outcome of this study was DMT discontinuation by 36-month follow-up. Secondary outcomes included reason for discontinuation (categorized as "Disease Activity," "Intolerance/Adverse Effects," or "Other"), time to discontinuation, and proportions with clinical relapse(s), brain MRI gadolinium-enhancing (GdE) lesions, brain MRI new T2-hyperintense lesions, brain MRI activity (a composite measure of GdE and new T2-hyperintense lesions), and absence of disease activity (defined as freedom from clinical relapses and brain MRI activity). All effectiveness endpoints for secondary outcomes were on-treatment measures.
For patients who discontinued therapy ≤ 36 months and had available data, additional outcomes were collected in the 12 months post-DMF/FTY discontinuation. These data included whether or not the patient switched to a new DMT, the type/efficacy of switched DMT (defined as "low efficacy"interferon-beta, glatiramer acetate, teriflunomide; "moderate efficacy"-DMF, FTY; or "high efficacy"natalizumab, rituximab, ocrelizumab, alemtuzumab), [20] [21] washout length, and the proportions with clinical relapse activity and brain MRI GdE lesions within 12 months of respective DMT discontinuation. The switched DMT was chosen at the discretion of the treating clinician and patient in a personalized medicine approach. 22 
Statistical Analysis
Statistical analyses were conducted using R version 3.5.0. 23 Two-tailed p-values <0.05 were considered statistically significant. For unadjusted estimates, differences between DMF and FTY were evaluated using t-tests for continuous data, χ 2 tests for categorical data, and Cox proportional hazards models and Kaplan-Meier curves for survival outcomes. We used PS methods identical to our 24-month study when conducting adjusted analyses. 13 The PS model was created using logistic regression to calculate the probability of initiating DMF, as compared to FTY, using a priori selected covariates including demographics and baseline J o u r n a l P r e -p r o o f clinical and MRI characteristics. All covariates were missing in fewer than 10% of patients. To determine the strength and selection of our PS method, we compared standardized differences in covariates pre-and post-adjustment. Excellent covariate balance was defined as an absolute standardized difference <10% between the covariate means across DMF and FTY. Before directly observing the study outcomes, we selected the best PS approach to make inferential conclusions on treatment effect differences based on the most complete covariate balance. To identify patients in the DMF and FTY groups with comparable baseline characteristics except for treatment, we derived a PS for each patient used in average treatment effect on the treated (ATT) weighting. We used the same approach as in our previous 12-and 24-month studies to account for missingness patterns. 13, 15, 17 For binary outcomes, conditional logistic regression was applied after ATT weighting to obtain odds ratio (OR) estimates comparing the treatment groups. Stratified Cox regression and Kaplan-Meier survival curves were used to evaluate survival data. All ORs and hazard ratios (HRs) refer to DMFtreated patients compared to those treated with FTY. Figure 1 demonstrates the overall study flow. A total of 1,272 patients were included in this study with baseline characteristics presented in Table 1 . Between 24-36 months of follow-up, 786 patients had available data (DMF n=428, FTY n=358). Differences between cohorts were observed in age, race, MS phenotype, last DMT prior to DMF or FTY, and baseline MRI lesion burden.
Results
Baseline Characteristics
Propensity Score Model
The PS model assigned higher PS to DMF compared to FTY with substantial PS overlap across the two DMTs ( Figure S1 ), demonstrating adequate comparability between the two treatment groups and confirming the appropriateness of using PS-adjusted techniques. The groups were not well-balanced prior to PS adjustment, as demonstrated by 4 covariates with absolute standardized differences >10% ( Figure S2 ). 13 Further, the absolute value of the standardized difference of the linear PS was 51.8%, comparing DMF to FTY. Through ATT weighting, we achieved well-balanced groups with no covariates having an absolute standardized difference greater than 10% and a comparable linear PS distribution with a standardized difference of 4.3%, well under the 50% standard proposed by Rubin. 24 
J o u r n a l P r e -p r o o f
Missing data among covariates in the PS model did not meaningfully change overall covariate balance after PS analysis. Tables 2 and 3 Of those who discontinued due to intolerance, the most common AEs for DMF were GI-related concerns, and the most common AEs for FTY were infections (Table S4) 
Discontinuation and Effectiveness Outcomes
Outcomes after DMF/FTY Discontinuation
A total of 573 patients had additional 12-month follow-up data after DMF or FTY discontinuation. (Table 4 ). Further, there were no cases of PML or other serious opportunistic infections during this time period.
Discussion
While RCTs provide the highest level of evidence for DMT safety and efficacy, comparing individual therapies in a pairwise fashion in robust clinical trials is cost-and time-prohibitive and have more limited applications in the clinical setting due to restrictive inclusion criteria. 25 Further, the anticipated approval of new MS medications that are not available at the time of trial initiation decreases the overall impact of such studies. However, advanced statistical methods such as PS-adjustment produce comparable cohorts using real-world data to allow head-to-head comparisons that can inform decision-making in routine practice with broad applicability.
We conducted a real-world, PS-adjusted, study directly comparing DMF versus FTY over 36 months in clinical practice. Individual sample sizes achieved by each center were similar to those used in the respective phase 3 clinical trials. [1] [2] [3] [4] Additionally, owing to our sizable proportions of discontinuations across both DMTs, we examined switching patterns and effectiveness outcomes in a subset of patients after discontinuing either DMF or FTY.
DMF-treated patients demonstrated higher odds of discontinuation compared to FTY-treated patients by 36 months, largely driven by intolerance. Our results also showed relatively greater DMF J o u r n a l P r e -p r o o f discontinuations compared to FTY, as were also reported by other observational studies. 11, 12, 16, 18, 26, 27 Interestingly, when accounting for patient censoring, there appeared to be a bimodal relationship of DMT discontinuation stratified by year of follow-up. For example, DMF patients had significantly greater odds of discontinuation between 0-12 months and 24-36 months, while discontinuations between 12-24 months were lower and comparable. This finding was further substantiated by our Kaplan-Meier analysis (Figure 2) . One explanation is that AEs more commonly expected with early DMF treatment, such as GI AEs and flushing, largely contributed to discontinuation patterns between 0-12 months. Other AEs, such as DMF-associated lymphopenia, which was the third leading cause of DMT cessation in our study, became more prominent as a reason for discontinuation during later treatment. This may have been due to the clinical recognition of the risks of sustained DMF-associated lymphopenia, as opposed to the time course of lymphopenia, for previous studies showed absolute lymphocyte count reductions occur commonly in the first year after DMF initiation. 28, 29 Additionally, during this study, revisions to DMF labeling recommended treatment interruption if prolonged lymphopenia occurred due to opportunistic infection risks (e.g. PML), which were observed in the open-label extension study and post-marketing experience. [28] [29] [30] In this context, these concerns likely drove our clinicians to discontinue DMF as risks became apparent based on later published research, not necessarily immediately after lymphopenia occurred in earlier treated patients. Further, there was no significant difference in discontinuation due to disease activity over 36 months, or when stratified by year of treatment. [13] [14] [15] [16] To our knowledge, there are no direct head-to-head published studies comparing DMF and FTY >30 months. The current study provides unique extension data to comment on the comparative effectiveness of DMF and FTY over 36 months of treatment. Clinical and radiological outcomes during this time period in our investigation remained low with similar disease activity between DMF and FTY, as was previously observed in other PS-adjusted analyses during shorter time intervals, 10, 12, 31, 32 though conflicting data showed reduced ARR among FTY-vs. DMF-treated patients in an international observational MS cohort study. 18 Our results demonstrated no differences in absence of disease activity between DMF and FTY in the overall cohort and RRMS subgroup. As previously discussed, 13 To date, no other study has reported switching patterns and comparative outcomes after discontinuing DMF versus FTY. In our study, approximately one third of DMF and FTY patients switched to HET, while more FTY patients switched to moderately effective therapy, likely due to later approval of DMF. In our PS-adjusted analysis, there were no significant differences in clinical relapses or GdE lesions in the 12 months following DMF discontinuation compared to the 12 months following FTY discontinuation, despite the longer washout period in the latter group. Further, there were no differences in relapses or GdE lesions in patients laterally switching to other moderately effective therapies, and overall disease activity remained low in this subgroup. Overall, DMF and FTY discontinuers who switched to HET had less disease activity compared to those switching to injectable and oral therapies. These results align with a large population-based study of patients with breakthrough disease who had reduced ARR and time to first relapse after switching to HET versus moderately effective DMT. 32 It is important to note that the FTY mechanism of action 33 likely played a role in the increased proportion of GdE lesions, relative to on-treatment, when transitioning to other therapies (in particular, non-HET DMTs). This finding underscores the importance of minimizing FTY washout duration and considering a switch to more highly efficacious therapies when clinically appropriate. Our data were also re-assuring from a safety standpoint in that no cases of PML or other opportunistic infections occurred in any of our patients on DMF/FTY or within 12 months of transitioning to an alternative DMT.
The current investigation had limitations owing to the assumptions inherent in observational studies, even after the application of PS techniques. While PS adjustment improved the overall baseline covariate balance between DMF and FTY, there are likely residual and hidden biases of unmeasured covariates. However, we believe the a priori covariates included in our PS model are important and well-representative of those used in DMT decision making in clinical practice. As a strength, we were able to include clinical and MRI data that are often unavailable through other sources, such as claims and some population-based data repositories. However, we were limited by retrospectively collected clinician-reported measurements (e.g. relapse) and missing data, which are integral limitations of J o u r n a l P r e -p r o o f retrospective observational studies. In addition, our investigation included older and progressive patients representative of the general MS population treated in clinical practice, for which the low inflammatory profiles may have obscured treatment effect differences. To address this, we included a separate subgroup analysis of RRMS patients, which allowed us to ascertain treatment effects in a population of patients similar to those in phase 3 clinical trials. Reassuringly, effectiveness outcomes in this subgroup were comparable to the overall cohort and adds further value to the observed endpoints. Finally, this study included data from two large academic MS centers, which may lessen generalizability to smaller community-based clinics that may differ in DMT prescribing practices and counseling.
Conclusion
Our results demonstrate comparable clinical and radiographic effectiveness of DMF and FTY in clinical practice over 36 months of treatment. We found increased odds of DMF discontinuation compared to FTY, largely driven by intolerance. In our cohort, there appeared to be a small rise in DMF discontinuations after the second year on therapy, which deserves further investigation. Reassuringly, patients transitioning from DMF and FTY to an alternative DMT demonstrated relatively low disease activity over the next 12 months, particularly when switching to HET. Future multi-center studies investigating the long-term comparative effectiveness profiles of DMF and FTY will provide further clinical insight on the use of these commonly prescribed oral DMTs in routine clinical practice. 
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